MedTrace Logo

Cyclosporine A in Cardiac Arrest

NCT01595958 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 796

Last updated 2025-08-28

No results posted yet for this study

Summary

The investigators hypothesised that cyclosporine A administration at the onset of cardiopulmonary resuscitation, by inhibiting the mitochondrial permeability transition pore, could prevent the post cardiac arrest syndrome and improve outcomes.

Conditions

  • Non Shockable Out of Hospital Cardiac Arrest

Interventions

DRUG

Cyclosporine A

Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation

PROCEDURE

cardio-pulmonary resuscitation

usual care of cardiac arrest

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Laurent ARGAUD, MD, PhD · Groupement Hospitalier Edouard Herriot,69437 Lyon Cedex 03

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01595958 on ClinicalTrials.gov